These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 27887792

  • 1. Edaravone with and without .6 Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5).
    Yamaguchi T, Awano H, Matsuda H, Tanahashi N, PROTECT4.5 Investigators.
    J Stroke Cerebrovasc Dis; 2017 Apr; 26(4):756-765. PubMed ID: 27887792
    [Abstract] [Full Text] [Related]

  • 2. Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes.
    Tanahashi N, Yamaguchi T, Awano H, Matsuda H.
    J Stroke Cerebrovasc Dis; 2018 May; 27(5):1302-1310. PubMed ID: 29373227
    [Abstract] [Full Text] [Related]

  • 3. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age.
    Kono S, Deguchi K, Morimoto N, Kurata T, Yamashita T, Ikeda Y, Narai H, Manabe Y, Takao Y, Kawada S, Kashihara K, Takehisa Y, Inoue S, Kiriyama H, Abe K.
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):1175-83. PubMed ID: 23507462
    [Abstract] [Full Text] [Related]

  • 4. Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator.
    Wada T, Yasunaga H, Inokuchi R, Horiguchi H, Fushimi K, Matsubara T, Nakajima S, Yahagi N.
    J Neurol Sci; 2014 Oct 15; 345(1-2):106-11. PubMed ID: 25085762
    [Abstract] [Full Text] [Related]

  • 5. Effects of edaravone, a free radical scavenger, on circulating levels of MMP-9 and hemorrhagic transformation in patients with intravenous thrombolysis using low-dose alteplase.
    Tsuruoka A, Atsumi C, Mizukami H, Imai T, Hagiwara Y, Hasegawa Y.
    J Stroke Cerebrovasc Dis; 2014 Oct 15; 23(10):2894-2899. PubMed ID: 25282183
    [Abstract] [Full Text] [Related]

  • 6. Simultaneous administration of recombinant tissue plasminogen activator and edaravone in acute cerebral ischemic stroke patients.
    Takenaka K, Kato M, Yamauti K, Hayashi K.
    J Stroke Cerebrovasc Dis; 2014 Oct 15; 23(10):2748-2752. PubMed ID: 25307430
    [Abstract] [Full Text] [Related]

  • 7. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S, Deguchi K, Morimoto N, Kurata T, Deguchi S, Yamashita T, Ikeda Y, Matsuura T, Narai H, Omori N, Manabe Y, Yunoki T, Takao Y, Kawata S, Kashihara K, Abe K.
    J Stroke Cerebrovasc Dis; 2013 Apr 15; 22(3):190-6. PubMed ID: 21968092
    [Abstract] [Full Text] [Related]

  • 8. Results of intravenous thrombolysis within 4.5 to 6 hours and updated results within 3 to 4.5 hours of onset of acute ischemic stroke recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR): an observational study.
    Ahmed N, Kellert L, Lees KR, Mikulik R, Tatlisumak T, Toni D, SITS Investigators.
    JAMA Neurol; 2013 Jul 15; 70(7):837-44. PubMed ID: 23689267
    [Abstract] [Full Text] [Related]

  • 9. Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain.
    Zhang W, Sato K, Hayashi T, Omori N, Nagano I, Kato S, Horiuchi S, Abe K.
    Neurol Res; 2004 Apr 15; 26(3):342-8. PubMed ID: 15142331
    [Abstract] [Full Text] [Related]

  • 10. Intravenous thrombolysis in young stroke patients: results from the SITS-ISTR.
    Toni D, Ahmed N, Anzini A, Lorenzano S, Brozman M, Kaste M, Mikulik R, Putaala J, Wahlgren N, SITS investigators.
    Neurology; 2012 Mar 20; 78(12):880-7. PubMed ID: 22402853
    [Abstract] [Full Text] [Related]

  • 11. YAMATO Study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy).
    Aoki J, Kimura K, Morita N, Harada M, Metoki N, Tateishi Y, Todo K, Yamagami H, Hayashi K, Terasawa Y, Fujita K, Yamamoto N, Deguchi I, Tanahashi N, Inoue T, Iwanaga T, Kaneko N, Mitsumura H, Iguchi Y, Ueno Y, Kuramoto Y, Ogata T, Fujimoto S, Yokoyama M, Nagahiro S, YAMATO Study Investigators.
    Stroke; 2017 Mar 20; 48(3):712-719. PubMed ID: 28119434
    [Abstract] [Full Text] [Related]

  • 12. Role of tissue plasminogen activator in acute ischemic stroke.
    Hatcher MA, Starr JA.
    Ann Pharmacother; 2011 Mar 20; 45(3):364-71. PubMed ID: 21386027
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and Safety of Intravenous Tenecteplase Bolus in Acute Ischemic Stroke: Results of Two Open-Label, Multicenter Trials.
    Ramakrishnan TCR, Kumaravelu S, Narayan SK, Buddha SS, Murali C, Majeed PHA, Meenakshi-Sundaram S, Wadia RS, Sharma V, Basu I, Vijaya P, Salam KA, Barmare S, Vaid Z, Nirmal Raj KK, Wattamwar PR, Asokan K, Dhonge V, Nellikunja S, Namjoshi D, Srinivasa R, Laddhad DS, Deshpande SD, Raghunath B, Kalita J, Kumar M, Misra UK, Pradeep M, Tenecteplase in Stroke Investigators.
    Am J Cardiovasc Drugs; 2018 Oct 20; 18(5):387-395. PubMed ID: 29948822
    [Abstract] [Full Text] [Related]

  • 14. Thrombolytic therapy for acute stroke in the United Kingdom: experience from the safe implementation of thrombolysis in stroke (SITS) register.
    Lees KR, Ford GA, Muir KW, Ahmed N, Dyker AG, Atula S, Kalra L, Warburton EA, Baron JC, Jenkinson DF, Wahlgren NG, Walters MR, SITS-UK Group.
    QJM; 2008 Nov 20; 101(11):863-9. PubMed ID: 18694900
    [Abstract] [Full Text] [Related]

  • 15. Relationship between magnetic resonance angiography-diffusion-weighted imaging mismatch and clinical outcome in endovascular treatment for acute ischemic stroke: subgroup analysis of the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism--Japan Registry.
    Deguchi I, Dembo T, Yoshimura S, Sakai N, Okada Y, Kitagawa K, Kimura K, Hyogo T, Yamagami H, Egashira Y, Tanahashi N.
    J Stroke Cerebrovasc Dis; 2014 Jul 20; 23(6):1471-6. PubMed ID: 24685994
    [Abstract] [Full Text] [Related]

  • 16. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
    Aoki S, Hosomi N, Sueda Y, Kono T, Takamatsu K, Ohyama H, Torii T, Kitamura T, Nomura E, Noda K, Ohtsuki T, Matsumoto M, HARP Registry Study Group.
    J Stroke Cerebrovasc Dis; 2015 Dec 20; 24(12):2747-53. PubMed ID: 26360972
    [Abstract] [Full Text] [Related]

  • 17. Thrombolysis with Low-Dose Tissue Plasminogen Activator 3-4.5 h After Acute Ischemic Stroke in Five Hospital Groups in Japan.
    Morihara R, Kono S, Sato K, Hishikawa N, Ohta Y, Yamashita T, Deguchi K, Manabe Y, Takao Y, Kashihara K, Inoue S, Kiriyama H, Abe K.
    Transl Stroke Res; 2016 Apr 20; 7(2):111-9. PubMed ID: 26815291
    [Abstract] [Full Text] [Related]

  • 18. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).
    Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y, Japan Alteplase Clinical Trial (J-ACT) Group.
    Stroke; 2006 Jul 20; 37(7):1810-5. PubMed ID: 16763187
    [Abstract] [Full Text] [Related]

  • 19. Factors predicting outcome in stroke patients treated with 0.6 mg/kg alteplase: evidence from the Japan Alteplase Clinical Trial (J-ACT).
    Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Japan Alteplase Clinical Trial (J-ACT) Group.
    J Stroke Cerebrovasc Dis; 2011 Nov 20; 20(6):517-22. PubMed ID: 20719535
    [Abstract] [Full Text] [Related]

  • 20. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS).
    Nakagawara J, Minematsu K, Okada Y, Tanahashi N, Nagahiro S, Mori E, Shinohara Y, Yamaguchi T, J-MARS Investigators.
    Stroke; 2010 Sep 20; 41(9):1984-9. PubMed ID: 20651262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.